[
  {
    "ts": null,
    "headline": "Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue",
    "summary": "Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.",
    "url": "https://finnhub.io/api/news?id=2d78abc9c521d5410a1b7a48cdb4537098c8b1423c3ba207e655bf50abb25221",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761336740,
      "headline": "Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue",
      "id": 137215393,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.",
      "url": "https://finnhub.io/api/news?id=2d78abc9c521d5410a1b7a48cdb4537098c8b1423c3ba207e655bf50abb25221"
    }
  },
  {
    "ts": null,
    "headline": "A GSK Cancer Drug Is Making a Comeback. It’s So-So News for the Stock.",
    "summary": "The Food and Drug Administration’s approval of the cancer drug Blenrep late Thursday offered some vindication for GSK, which has been battling for years to get the treatment back on the market, but the details weren’t quite good enough to satisfy investors.  GSK  American depositary receipts jumped in the final moments of trading on Thursday, when news of the approval crossed the wire.  As investors examined the company update, however, sentiment reversed.",
    "url": "https://finnhub.io/api/news?id=9f02ef810ac744fccab14ebf9cb9d0df8a18cfbf16ffef74f15639a6b2efa49f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761322020,
      "headline": "A GSK Cancer Drug Is Making a Comeback. It’s So-So News for the Stock.",
      "id": 137216546,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration’s approval of the cancer drug Blenrep late Thursday offered some vindication for GSK, which has been battling for years to get the treatment back on the market, but the details weren’t quite good enough to satisfy investors.  GSK  American depositary receipts jumped in the final moments of trading on Thursday, when news of the approval crossed the wire.  As investors examined the company update, however, sentiment reversed.",
      "url": "https://finnhub.io/api/news?id=9f02ef810ac744fccab14ebf9cb9d0df8a18cfbf16ffef74f15639a6b2efa49f"
    }
  },
  {
    "ts": null,
    "headline": "PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?",
    "summary": "Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength",
    "url": "https://finnhub.io/api/news?id=daf3a6aae1e2b200b1008e7195bb28c4df1f3015d149ee5dc3c74f4a45801889",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761319800,
      "headline": "PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?",
      "id": 137216547,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength",
      "url": "https://finnhub.io/api/news?id=daf3a6aae1e2b200b1008e7195bb28c4df1f3015d149ee5dc3c74f4a45801889"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings",
    "summary": "LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",
    "url": "https://finnhub.io/api/news?id=6628e9017c13810d4e5dd87125653beb0cd4b2cd310bbc6c24dc78e8d13c7010",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761312540,
      "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings",
      "id": 137215925,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.",
      "url": "https://finnhub.io/api/news?id=6628e9017c13810d4e5dd87125653beb0cd4b2cd310bbc6c24dc78e8d13c7010"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=7764b7deb2174b5f3b1b51d3e7f0dc2ccb5ba42e205feb5b9258f1275aa2c962",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761310803,
      "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137216549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=7764b7deb2174b5f3b1b51d3e7f0dc2ccb5ba42e205feb5b9258f1275aa2c962"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer's Headwinds May Already Be In The Price",
    "summary": "Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.",
    "url": "https://finnhub.io/api/news?id=34268297a9da89cd4aa1ae6b900ca37bd3b9ce594c7e1f7b7eb046c5a729e298",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761309954,
      "headline": "Why Pfizer's Headwinds May Already Be In The Price",
      "id": 137202809,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689040811/image_1689040811.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.",
      "url": "https://finnhub.io/api/news?id=34268297a9da89cd4aa1ae6b900ca37bd3b9ce594c7e1f7b7eb046c5a729e298"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore",
    "summary": "Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, \"BioNTech\") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore as the first country in Southeast Asia to receive full approval for the latest COVID-19 vaccine.",
    "url": "https://finnhub.io/api/news?id=3bfea3a0063e15504e9030fc365a915c8d3fd7706a7a760b4baf6569fa29e7da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761298380,
      "headline": "Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore",
      "id": 137216550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, \"BioNTech\") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore as the first country in Southeast Asia to receive full approval for the latest COVID-19 vaccine.",
      "url": "https://finnhub.io/api/news?id=3bfea3a0063e15504e9030fc365a915c8d3fd7706a7a760b4baf6569fa29e7da"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue",
    "summary": "Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher revenue and adjusted earnings.",
    "url": "https://finnhub.io/api/news?id=dc18cb6d0ed40579a1d5d3277b1879fa1c82349c7645503a37857e06f8848bce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761295500,
      "headline": "Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue",
      "id": 137215401,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher revenue and adjusted earnings.",
      "url": "https://finnhub.io/api/news?id=dc18cb6d0ed40579a1d5d3277b1879fa1c82349c7645503a37857e06f8848bce"
    }
  },
  {
    "ts": null,
    "headline": "Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs",
    "summary": "Discover 9 top high-yield dividend stocks with attractive prices and strong growth forecasts.",
    "url": "https://finnhub.io/api/news?id=8c1303e07f4fc864c75cdba24cdfab801237daac14696e3a104a86411eda40de",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761292480,
      "headline": "Buy 9 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 October Dividend Dogs",
      "id": 137201845,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1354829469/image_1354829469.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 9 top high-yield dividend stocks with attractive prices and strong growth forecasts.",
      "url": "https://finnhub.io/api/news?id=8c1303e07f4fc864c75cdba24cdfab801237daac14696e3a104a86411eda40de"
    }
  },
  {
    "ts": null,
    "headline": "What Do Advances in Pfizer’s Vaccine Pipeline Mean for Its 2025 Valuation?",
    "summary": "If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller coaster for this healthcare heavyweight, and plenty of investors are watching closely. Should you hold, buy more, or consider moving on? Let’s start by looking at what’s been moving the needle recently. Pfizer’s shares are up 1.8% over the last week and have gained 2.2% over the past month. But zooming out gives a different angle, with the stock down 7.3% year-to-date...",
    "url": "https://finnhub.io/api/news?id=9693bf0ae892909d80dba7a3872377d13afdc62a2a5533ce5abd7b48ec1b2ba6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761275792,
      "headline": "What Do Advances in Pfizer’s Vaccine Pipeline Mean for Its 2025 Valuation?",
      "id": 137216552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller coaster for this healthcare heavyweight, and plenty of investors are watching closely. Should you hold, buy more, or consider moving on? Let’s start by looking at what’s been moving the needle recently. Pfizer’s shares are up 1.8% over the last week and have gained 2.2% over the past month. But zooming out gives a different angle, with the stock down 7.3% year-to-date...",
      "url": "https://finnhub.io/api/news?id=9693bf0ae892909d80dba7a3872377d13afdc62a2a5533ce5abd7b48ec1b2ba6"
    }
  }
]